,drug,MOAs
161,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|src inhibitor
52,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,FLT3 inhibitor|KIT inhibitor|PKC inhibitor
60,CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](CC(=O)NO)CC(C)C,matrix metalloprotease inhibitor
92,CN1c2ccccc2C(=O)N2CCc3c([nH]c4ccccc34)C21,ATPase inhibitor|TRPV agonist
67,CC1CC(C)C(=O)C(C(O)CC2CC(=O)NC(=O)C2)C1,protein synthesis inhibitor
